NASDAQ:PODD Insulet (PODD) Stock Forecast, Price & News $272.58 -0.05 (-0.02%) (As of 04:00 PM ET) Add Compare Share Share Today's Range$271.47▼$276.2550-Day Range$272.63▼$330.2352-Week Range$192.33▼$335.91Volume501,674 shsAverage Volume725,469 shsMarket Capitalization$19.00 billionP/E Ratio233.02Dividend YieldN/APrice Target$330.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Insulet MarketRank™ ForecastAnalyst RatingHold2.46 Rating ScoreUpside/Downside21.0% Upside$330.00 Price TargetShort InterestHealthy4.65% of Shares Sold ShortDividend StrengthN/ASustainability-1.20Upright™ Environmental ScoreNews Sentiment0.91Based on 12 Articles This WeekInsider TradingSelling Shares$9.82 M Sold Last QuarterProj. Earnings Growth49.64%From $1.37 to $2.05 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.35 out of 5 starsMedical Sector278th out of 1,009 stocksSurgical & Medical Instruments Industry30th out of 104 stocks 2.2 Analyst's Opinion Consensus RatingInsulet has received a consensus rating of Hold. The company's average rating score is 2.46, and is based on 6 buy ratings, 7 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $330.00, Insulet has a forecasted upside of 21.0% from its current price of $272.78.Amount of Analyst CoverageInsulet has only been the subject of 3 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted4.65% of the outstanding shares of Insulet have been sold short.Short Interest Ratio / Days to CoverInsulet has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Insulet has recently decreased by 1.52%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldInsulet does not currently pay a dividend.Dividend GrowthInsulet does not have a long track record of dividend growth. Previous Next 4.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreInsulet has received a 80.74% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Insulin pumps" product. See details.Environmental SustainabilityThe Environmental Impact score for Insulet is -1.20. Previous Next 3.3 News and Social Media Coverage News SentimentInsulet has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Insulet this week, compared to 6 articles on an average week.Search Interest18 people have searched for PODD on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added Insulet to their MarketBeat watchlist in the last 30 days. This is a decrease of -14% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Insulet insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,819,174.00 in company stock.Percentage Held by InsidersOnly 0.80% of the stock of Insulet is held by insiders. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Insulet are expected to grow by 49.64% in the coming year, from $1.37 to $2.05 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Insulet is 233.02, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 129.56.Price to Earnings Ratio vs. SectorThe P/E ratio of Insulet is 233.02, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 97.74.Price to Earnings Growth RatioInsulet has a PEG Ratio of 5.66. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioInsulet has a P/B Ratio of 39.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Insulet (NASDAQ:PODD) StockInsulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.Read More Receive PODD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Insulet and its competitors with MarketBeat's FREE daily newsletter. Email Address PODD Stock News HeadlinesMay 30, 2023 | americanbankingnews.comInsulet Co. to Post Q1 2024 Earnings of $0.32 Per Share, William Blair Forecasts (NASDAQ:PODD)May 29, 2023 | finance.yahoo.comInsiders Pour Millions Into These 2 Beaten-Down Stocks, Analysts Say They Could Be Ready to Bounce Back — Here’s Why You Should Pay AttentionMay 30, 2023 | Legacy Research (Affiliate) (Ad)Sell every Stock except ONE Markets are down...But Jeff Clark couldn't care less because he ignores almost every stock in the market except ONE. He lives financially free trading this One Stock Once per month...May 29, 2023 | americanbankingnews.comInsulet Co. (NASDAQ:PODD) Given Average Rating of "Hold" by AnalystsMay 25, 2023 | markets.businessinsider.comBTIG Sticks to Its Buy Rating for Insulet (PODD)May 25, 2023 | msn.comInsulet, Tandem fall as Medtronic to buy insulin pump makerMay 23, 2023 | forbes.comHow Insulet Delivered On Its 360-Degree Promise To People With DiabetesMay 22, 2023 | finance.yahoo.comHAE or PODD: Which Is the Better Value Stock Right Now?May 30, 2023 | Behind the Markets (Ad)AI Creates New Cancer Drug - In Just 30 Days!On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...May 22, 2023 | americanbankingnews.comStockNews.com Begins Coverage on Insulet (NASDAQ:PODD)May 20, 2023 | americanbankingnews.comWilliam Blair Comments on Insulet Co.'s Q3 2023 Earnings (NASDAQ:PODD)May 19, 2023 | americanbankingnews.comWilliam Blair Comments on Insulet Co.'s Q2 2023 Earnings (NASDAQ:PODD)May 17, 2023 | msn.comInsulet Earnings Perspective: Return On Capital EmployedMay 15, 2023 | finance.yahoo.comInsulet (NASDAQ:PODD) shareholder returns have been splendid, earning 271% in 5 yearsMay 15, 2023 | americanbankingnews.comInsulet Co. (NASDAQ:PODD) Short Interest UpdateMay 10, 2023 | msn.comBarclays Maintains Insulet (PODD) Equal-Weight RecommendationMay 10, 2023 | americanbankingnews.comInsulet (NASDAQ:PODD) PT Raised to $329.00 at BarclaysMay 8, 2023 | finance.yahoo.comAbbott (ABT) EPD Business Grows Strong, Macro Issues StayMay 8, 2023 | finance.yahoo.comHere's How Insulet Could Continue to Reward ShareholdersMay 6, 2023 | americanbankingnews.comInsulet (NASDAQ:PODD) Price Target Raised to $360.00 at UBS GroupMay 6, 2023 | americanbankingnews.comInsulet (NASDAQ:PODD) Price Target Raised to $370.00 at Robert W. BairdMay 5, 2023 | finance.yahoo.comInsulet (PODD) Q1 Earnings Beat Estimates, Sales View UpMay 5, 2023 | finance.yahoo.comNew Highs: Diabetes Stock Breaks Out. Cement Maker Surges Past Buy Point.May 5, 2023 | finance.yahoo.comQ1 2023 Insulet Corp Earnings CallMay 5, 2023 | americanbankingnews.comInsulet (NASDAQ:PODD) Price Target Increased to $360.00 by Analysts at Piper SandlerMay 5, 2023 | seekingalpha.comInsulet Corporation 2023 Q1 - Results - Earnings Call PresentationMay 4, 2023 | finance.yahoo.comInsulet Reports First Quarter 2023 Revenue Increase of 21% Year-Over-Year (23% Constant Currency1)See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive PODD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Insulet and its competitors with MarketBeat's FREE daily newsletter. Email Address PODD Company Calendar Last Earnings5/04/2023Today5/30/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNASDAQ:PODD CUSIP45784P10 CIK1145197 Webwww.insulet.com Phone(978) 600-7000Fax978-600-0120Employees2,600Year Founded2000Price Target and Rating Average Stock Price Forecast$330.00 High Stock Price Forecast$370.00 Low Stock Price Forecast$260.00 Forecasted Upside/Downside+21.0%Consensus RatingHold Rating Score (0-4)2.46 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio233.02 Forward P/E Ratio199.00 P/E Growth5.66Net Income$4.60 million Net Margins0.04% Pretax Margin0.37% Return on Equity17.29% Return on Assets3.59% Debt Debt-to-Equity Ratio2.72 Current Ratio3.47 Quick Ratio2.46 Sales & Book Value Annual Sales$1.31 billion Price / Sales14.56 Cash Flow$2.22 per share Price / Cash Flow122.71 Book Value$6.86 per share Price / Book39.74Miscellaneous Outstanding Shares69,700,000Free Float69,138,000Market Cap$19.00 billion OptionableOptionable Beta0.80 Social Links Key ExecutivesJames R. HollingsheadPresident, Chief Executive Officer & DirectorPrem SinghSenior Vice President-Global OperationsWayde Dwight McMillanChief Financial Officer, Treasurer & Executive VPTrang LySenior Vice President & Medical DirectorMark FieldGroup Vice President-Software EngineeringKey CompetitorsBaxter InternationalNYSE:BAXTeleflexNYSE:TFXResMedNYSE:RMDGlobus MedicalNYSE:GMEDDexComNASDAQ:DXCMView All CompetitorsInsiders & InstitutionsProShare Advisors LLCBought 9,699 shares on 5/26/2023Ownership: 0.015%Toroso Investments LLCBought 368 shares on 5/23/2023Ownership: 0.004%American TrustSold 336 shares on 5/22/2023Ownership: 0.002%New York State Common Retirement FundSold 18,473 shares on 5/18/2023Ownership: 0.110%Centaurus Financial Inc.Bought 334 shares on 5/18/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions PODD Stock - Frequently Asked Questions Should I buy or sell Insulet stock right now? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last twelve months. There are currently 7 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" PODD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PODD, but not buy additional shares or sell existing shares. View PODD analyst ratings or view top-rated stocks. What is Insulet's stock price forecast for 2023? 13 brokerages have issued 12-month price targets for Insulet's shares. Their PODD share price forecasts range from $260.00 to $370.00. On average, they anticipate the company's stock price to reach $330.00 in the next twelve months. This suggests a possible upside of 20.5% from the stock's current price. View analysts price targets for PODD or view top-rated stocks among Wall Street analysts. How have PODD shares performed in 2023? Insulet's stock was trading at $294.39 at the beginning of the year. Since then, PODD shares have decreased by 7.0% and is now trading at $273.75. View the best growth stocks for 2023 here. When is Insulet's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our PODD earnings forecast. How were Insulet's earnings last quarter? Insulet Co. (NASDAQ:PODD) posted its earnings results on Thursday, May, 4th. The medical instruments supplier reported $0.23 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.14. The medical instruments supplier earned $358.10 million during the quarter, compared to the consensus estimate of $330.21 million. Insulet had a trailing twelve-month return on equity of 17.29% and a net margin of 0.04%. The firm's revenue was up 21.2% compared to the same quarter last year. During the same period last year, the firm earned $0.40 earnings per share. What ETFs hold Insulet's stock? ETFs with the largest weight of Insulet (NASDAQ:PODD) stock in their portfolio include First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Fidelity Digital Health ETF (FDHT), Vesper U.S. Large Cap Short-Term Reversal Strategy ETF (UTRN), Goldman Sachs Future Health Care Equity ETF (GDOC), Subversive Mental Health ETF (SANE), Invesco Focused Discovery Growth ETF (IVDG), Harbor Health Care ETF (MEDI) and Nuveen ESG Mid-Cap Growth ETF (NUMG). What guidance has Insulet issued on next quarter's earnings? Insulet updated its second quarter 2023 earnings guidance on Thursday, May, 4th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $380.24 million-$389.22 million, compared to the consensus revenue estimate of $362.68 million. What is Shacey Petrovic's approval rating as Insulet's CEO? 61 employees have rated Insulet Chief Executive Officer Shacey Petrovic on Glassdoor.com. Shacey Petrovic has an approval rating of 55% among the company's employees. This puts Shacey Petrovic in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Insulet own? Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include NVIDIA (NVDA), DexCom (DXCM), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Block (SQ), Walt Disney (DIS), Salesforce (CRM), Roku (ROKU) and Trade Desk (TTD). What is Insulet's stock symbol? Insulet trades on the NASDAQ under the ticker symbol "PODD." Who are Insulet's major shareholders? Insulet's stock is owned by many different institutional and retail investors. Top institutional investors include Price T Rowe Associates Inc. MD (3.24%), Clearbridge Investments LLC (2.24%), Geode Capital Management LLC (2.13%), Bank of New York Mellon Corp (0.83%), Gateway Advisory LLC (0.79%) and William Blair Investment Management LLC (0.69%). Insiders that own company stock include Bret Christensen, Charles Alpuche, Dan Manea, Eric Benjamin, John A Fallon, Michael P Spears, Sally Crawford, Shacey Petrovic and Wayde D Mcmillan. View institutional ownership trends. How do I buy shares of Insulet? Shares of PODD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Insulet's stock price today? One share of PODD stock can currently be purchased for approximately $273.75. How much money does Insulet make? Insulet (NASDAQ:PODD) has a market capitalization of $19.08 billion and generates $1.31 billion in revenue each year. How many employees does Insulet have? The company employs 2,600 workers across the globe. How can I contact Insulet? Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The official website for the company is www.insulet.com. The medical instruments supplier can be reached via phone at (978) 600-7000, via email at ir@insulet.com, or via fax at 978-600-0120. This page (NASDAQ:PODD) was last updated on 5/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Insulet Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.